Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxue Qingnao Pill in Mild Vascular Cognitive Impairment
NCT04958512Completed
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Yangxueqingnao in vascular cognitive impairment (VCI), sponsored by Peking University Third Hospital. Primary endpoint: Montreal Cognitive Assessment at 6 months. Started Aug 2017; status: completed.
02
Drugs
Yangxueqingnao
03
Conditions
vascular cognitive impairment (VCI)
Beyond the preview
Go deeper on NCT04958512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958512.